MY149448A - Interleukin-21 receptor binding proteins - Google Patents

Interleukin-21 receptor binding proteins

Info

Publication number
MY149448A
MY149448A MYPI2010005509A MYPI20105509A MY149448A MY 149448 A MY149448 A MY 149448A MY PI2010005509 A MYPI2010005509 A MY PI2010005509A MY PI20105509 A MYPI20105509 A MY PI20105509A MY 149448 A MY149448 A MY 149448A
Authority
MY
Malaysia
Prior art keywords
binding proteins
interleukin
receptor binding
disorders
receptor
Prior art date
Application number
MYPI2010005509A
Other languages
English (en)
Inventor
Bloom Laird
Gill Davinder
Vugmeyster Yulia
Deborah A Young
Lowe David
Valge-Archer Viia
Original Assignee
Wyeth Llc
Medimmune Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41112652&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MY149448(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Wyeth Llc, Medimmune Ltd filed Critical Wyeth Llc
Publication of MY149448A publication Critical patent/MY149448A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Pulmonology (AREA)
  • Transplantation (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
MYPI2010005509A 2008-05-23 2009-05-26 Interleukin-21 receptor binding proteins MY149448A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US5550008P 2008-05-23 2008-05-23

Publications (1)

Publication Number Publication Date
MY149448A true MY149448A (en) 2013-08-30

Family

ID=41112652

Family Applications (1)

Application Number Title Priority Date Filing Date
MYPI2010005509A MY149448A (en) 2008-05-23 2009-05-26 Interleukin-21 receptor binding proteins

Country Status (20)

Country Link
US (2) US8163884B2 (enExample)
EP (1) EP2297199A1 (enExample)
JP (1) JP2011523849A (enExample)
KR (1) KR20110040773A (enExample)
CN (1) CN102105491A (enExample)
AR (1) AR071885A1 (enExample)
AU (1) AU2009248809A1 (enExample)
CA (1) CA2724915A1 (enExample)
CL (1) CL2009001284A1 (enExample)
CO (1) CO6382184A2 (enExample)
IL (1) IL209328A0 (enExample)
MX (1) MX2010012811A (enExample)
MY (1) MY149448A (enExample)
NZ (1) NZ589330A (enExample)
PE (1) PE20100141A1 (enExample)
RU (1) RU2010152690A (enExample)
SA (1) SA109300315B1 (enExample)
TW (1) TW201000129A (enExample)
WO (1) WO2009143523A1 (enExample)
ZA (1) ZA201008335B (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6057128A (en) 1998-03-17 2000-05-02 Genetics Institute, Inc. MU-1, member of the cytokine receptor family
EP2518084B1 (en) * 2009-12-25 2016-11-30 Sekisui Medical Co., Ltd. Method for measuring human insulin and measurement reagent
EP2545080B1 (en) * 2010-03-12 2017-05-10 Alexion Pharmaceuticals, Inc. Npp1 fusion proteins
US9309318B2 (en) * 2012-10-17 2016-04-12 Amgen, Inc. Compositions relating to anti-IL-21 receptor antibodies
US20190185559A1 (en) * 2016-09-02 2019-06-20 The Brigham And Women's Hospital, Inc. Compositions and methods for treating neoplasias
US12134790B2 (en) 2017-09-27 2024-11-05 Inozyme Pharma, Inc. Methods of improving cardiovascular function and treating cardiovascular disease using a recombinant ectonucleotide pyrophosphatase phosphodiesterase (NPP1)
EP4162036A1 (en) 2020-06-09 2023-04-12 Inozyme Pharma, Inc. Soluble enpp1 or enpp3 proteins and uses thereof
US12012441B2 (en) 2020-10-26 2024-06-18 Neptune Biosciences Llc Engineered human IL-21 cytokines and methods for using the same
WO2024040195A1 (en) 2022-08-17 2024-02-22 Capstan Therapeutics, Inc. Conditioning for in vivo immune cell engineering

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7198789B2 (en) * 1998-03-17 2007-04-03 Genetics Institute, Llc Methods and compositions for modulating interleukin-21 receptor activity
US7189400B2 (en) * 1998-03-17 2007-03-13 Genetics Institute, Llc Methods of treatment with antagonists of MU-1
US6057128A (en) * 1998-03-17 2000-05-02 Genetics Institute, Inc. MU-1, member of the cytokine receptor family
US6576744B1 (en) * 1998-09-23 2003-06-10 Zymogenetics, Inc. Cytokine receptor zalpha11
UA84387C2 (ru) 1999-03-09 2008-10-27 Займодженетикс, Инк. Человеческий цитокин как лиганд зальфа рецептора и его применение
US6307024B1 (en) * 1999-03-09 2001-10-23 Zymogenetics, Inc. Cytokine zalpha11 Ligand
WO2000069880A1 (en) 1999-05-18 2000-11-23 Millennium Pharmaceuticals, Inc. Il-9/il-2 receptor-like molecules and uses thereof
ES2279809T3 (es) * 2000-04-05 2007-09-01 Zymogenetics, Inc. Receptores de citoquina zalfa11 solubles.
ATE346864T1 (de) 2000-05-11 2006-12-15 Genetics Inst Llc Mu-1, ein mitglied der cytokine rezeptor familie
EP2130919A1 (en) * 2001-11-05 2009-12-09 ZymoGenetics, Inc. IL-21 antagonists
US20040016010A1 (en) * 2002-04-17 2004-01-22 Marion Kasaian IL-21 receptor knockout animal and methods of use thereof
MXPA04012116A (es) * 2002-06-07 2005-04-19 Zymogenetics Inc Uso del il-21 en cancer y otras aplicaciones terapeuticas.
MXPA05000655A (es) * 2002-07-15 2006-02-22 Harvard College Metodos y composiciones para modular el desarrollo y la funcion de las celulas t helper (th).
MXPA05009556A (es) * 2003-03-14 2005-11-16 Wyeth Corp Anticuerpos contra receptor de il-21 humano y sus usos.
RU2005132458A (ru) * 2003-03-21 2006-03-20 Уайт (Us) Лечение иммунологических расстройств с использованием агонистов интерлейкина-21/рецептора интерлейкина-21
US7276478B2 (en) * 2003-09-25 2007-10-02 Zymogenetics, Inc. Methods of treating autoimmune diseases using IL-21
EP1753458A4 (en) * 2004-05-19 2009-07-22 Wyeth Corp MODULATION OF IMMUNOGLOBULIN PRODUCTION AND ATOPIC DISORDERS
MX2007001509A (es) 2004-08-05 2007-03-27 Wyeth Corp Antagonismo de la actividad del receptor de interleuquina 21.
CN101052419A (zh) * 2004-08-05 2007-10-10 惠氏公司 拮抗白介素－21受体活性
GT200600148A (es) * 2005-04-14 2006-11-22 Metodos para el tratamiento y la prevencion de fibrosis
WO2008081198A1 (en) 2007-01-05 2008-07-10 Imperial Innovations Ltd Blood assays for predicting inflammatory responses

Also Published As

Publication number Publication date
AR071885A1 (es) 2010-07-21
IL209328A0 (en) 2011-01-31
CN102105491A (zh) 2011-06-22
AU2009248809A1 (en) 2009-11-26
CL2009001284A1 (es) 2009-11-27
WO2009143523A1 (en) 2009-11-26
US20120264919A1 (en) 2012-10-18
JP2011523849A (ja) 2011-08-25
EP2297199A1 (en) 2011-03-23
SA109300315B1 (ar) 2012-08-28
ZA201008335B (en) 2014-04-30
PE20100141A1 (es) 2010-02-22
RU2010152690A (ru) 2012-06-27
MX2010012811A (es) 2011-05-19
KR20110040773A (ko) 2011-04-20
TW201000129A (en) 2010-01-01
NZ589330A (en) 2012-12-21
US20090298167A1 (en) 2009-12-03
CO6382184A2 (es) 2012-02-15
CA2724915A1 (en) 2009-11-26
US8163884B2 (en) 2012-04-24

Similar Documents

Publication Publication Date Title
MY146664A (en) Antibodies against human il-22 and uses therefor
EP1603949B8 (en) Antibodies against human il-21 receptor and uses therefor
MY160590A (en) Cd127 binding proteins
TW200744634A (en) Methods of using antibodies against human IL-22
PH12013500564A1 (en) Anti-cd48 antibodies and uses thereof
NZ599875A (en) Human il-23 antigen binding proteins
PH12014502527B1 (en) St2 antigen binding proteins
PH12012500843A1 (en) Engineered anti-tslp antibody
TN2011000528A1 (en) Compositions and methods for antibodies targeting complement protein c3b
EA201790330A1 (ru) Белки, связывающиеся с bcma (cd269/tnfrsf17)
WO2014114651A9 (en) Tnf-alpha antigen-binding proteins
PH12016500425B1 (en) Il-18 binding protein (il-18bp) in inflammatory diseases
PH12013502205A1 (en) Antibodies to il-6 and their uses
PH12013500356A1 (en) Engineered anti-tslp antibody
EA201492253A1 (ru) Конструкторы, связывающиеся с ron, и способы их использования
EP3219725A3 (en) Dkk1 antibodies and methods of use
MY150242A (en) Antigen binding proteins capable of binding thymic stromal lymphopoietin
NZ589330A (en) Interleukin-21 receptor binding proteins
AR072136A1 (es) Metodos de tratamiento que utilizan proteinas de union del receptor de in-terleuquina 21
PH12021551422A1 (en) Anti-il-36 antibodies and methods of use thereof
ECSP056015A (es) Anticuerpos contra el receptor de il-21 humano y usos de los mismos